agradecimiento-compra

Bibliography

CHAPTER 1

  • Hofmann, A., & Ott, J. (1980). LSD, my problem child (Vol. 5). New York: McGraw-Hill.

  • Shulgin, A., & Shulgin, A. (1992). PiHKAL. A chemical love story, 1991.

  • Shulgin, A. T., & Shulgin, A. (1997). TIHKAL: the continuation (Vol. 546). Berkeley, CA: Transform press.

CHAPTER 2

  • Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., … & Knudsen, G. M. (2017). A high-resolution in vivo atlas of the human brain’s serotonin system. Journal of Neuroscience, 37(1), 120-128.

  • Buckner, R. L., & Krienen, F. M. (2013). The evolution of distributed association networks in the human brain. Trends in cognitive sciences, 17(12), 648-665.

  • Margulies, D. S., Ghosh, S. S., Goulas, A., Falkiewicz, M., Huntenburg, J. M., Langs, G., … & Smallwood, J. (2016). Situating the default-mode network along a principal gradient of macroscale cortical organization. Proceedings of the National Academy of Sciences, 113(44), 12574-12579.

  • Nadal MS y Amarillo Y. El tálamo en el centro de la atención. Ciencia Hoy. 2018.27(160):36-40.

  • Shipp, S. (2016). Neural elements for predictive coding. Frontiers in psychology, 7, 1792.

  • Yeo, B. T., Krienen, F. M., Sepulcre, J., Sabuncu, M. R., Lashkari, D., Hollinshead, M., … & Buckner, R. L. (2011). The organization of the human cerebral cortex estimated by intrinsic functional connectivity. Journal of neurophysiology.

CHAPTER 3

Clinical studies with classic psychedelics:

  • Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., … & Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155-166.

  • Becker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., … & Liechti, M. E. (2021). Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects. Clinical Pharmacology & Therapeutics.

  • Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of psychopharmacology, 29(3), 289-299.

  • Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., … & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627.

  • Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., … & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 235(2), 399-408.

  • Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., … & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402-1411.

  • Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., … & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA psychiatry, 78(5), 481-489.

  • Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of nervous and mental disease, 202(7), 513.

  • Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., … & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology, 30(12), 1181-1197.

  • Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of general psychiatry, 68(1), 71-78.

  • Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of psychopharmacology, 28(11), 983-992.

  • Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American journal of drug and alcohol abuse, 43(1), 55-60.

  • Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. The Journal of clinical psychiatry, 67(11), 18864.

  • Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(9752), 1558-1565.

  • Osório, F. D. L., Sanches, R. F., Macedo, L. R., Dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., … & Hallak, J. E. (2015). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Brazilian Journal of Psychiatry, 37, 13-20.

  • Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., … & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology, 30(12), 1165-1180.

Clinical studies with MDMA:

  • Danforth Alicia L., Struble Christopher M., Yazar-Klosinski Berra, Grob Charles S., Danforth Alicia L., MDMA-Assisted Therapy: A New Treatment Paradigm for Autistic Adults with Social Anxiety, Progress in Neuropsychopharmacology & Biological Psychiatry (2015), doi: 10.1016/j.pnpbp.2015.03.011

  • Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., … & Emerson, A. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 235(11), 3137-3148.

  • Danforth, A. L. (2019). Embracing neurodiversity in psychedelic science: A mixed-methods inquiry into the MDMA experiences of autistic adults. Journal of psychoactive drugs, 51(2), 146-154.

  • Jerome, L., Feduccia, A. A., Wang, J. B., Hamilton, S., Klosinski, B., Emerson, A., … & Doblin, R. (2020). Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology, 237(8), 2485-2497.

  • Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., … & Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025-1033.

  • Mithoefer, M. C., Designee, S., Doblin, R., & Emerson, A. (2008). A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder.

  • Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of±3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of psychopharmacology, 25(4), 439-452.

  • Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., … & Doblin, R. (2019). MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology, 236(9), 2735-2745.

  • Sessa, B., Sakal, C., O’Brien, S., & Nutt, D. (2019). First study of safety and tolerability of 3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. BMJ Case Reports CP, 12(7), e230109.

CHAPTER 4:

  • Alamia, A., Timmermann, C., Nutt, D. J., VanRullen, R., & Carhart-Harris, R. L. (2020). DMT alters cortical travelling waves. Elife, 9, e59784.

  • Alexander, B. K. (2015). Healing addiction through community: A much longer road than it seems. In Creating Caring Communities Conference.

  • Baggott, M. J. (2015). Psychedelics and creativity: a review of the quantitative literature. PeerJ PrePrints, 3, e1202v1.

  • Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports, 10(1), 1-14.

  • Bershad, A. K., Preller, K. H., Lee, R., Keedy, S., Wren-Jarvis, J., Bremmer, M. P., & de Wit, H. (2020). Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 5(4), 461-467.

  • Carhart-Harris, R. L., Wall, M. B., Erritzoe, D., Kaelen, M., Ferguson, B., De Meer, I., … & Nutt, D. J. (2014). The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. International Journal of Neuropsychopharmacology, 17(4), 527-540.

  • Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., … & Nutt, D. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in human neuroscience, 20.

  • Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., … & Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences, 113(17), 4853-4858.

  • Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., … & Nutt, D. J. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific reports, 7(1), 1-11.

  • Fadiman, J. (2011). The psychedelic explorer’s guide: Safe, therapeutic, and sacred journeys. Simon and Schuster.

  • Family, N., Vinson, D., Vigliocco, G., Kaelen, M., Bolstridge, M., Nutt, D. J., & Carhart-Harris, R. L. (2016). Semantic activation in LSD: evidence from picture naming. Language, Cognition and Neuroscience, 31(10), 1320-1327.

  • Grimm, O., Kraehenmann, R., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2018). Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. European Neuropsychopharmacology, 28(6), 691-700.

  • Hubbard, E. M., & Ramachandran, V. S. (2005). Neurocognitive mechanisms of synesthesia. Neuron, 48(3), 509-520.

  • Kaelen, M., Roseman, L., Kahan, J., Santos-Ribeiro, A., Orban, C., Lorenz, R., … & Carhart-Harris, R. (2016). LSD modulates music-induced imagery via changes in parahippocampal connectivity. European Neuropsychopharmacology, 26(7), 1099-1109.

  • Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012). Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biological psychiatry, 72(11), 898-906.

  • Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015). Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological psychiatry, 78(8), 572-581.

  • Kraehenmann, R., Schmidt, A., Friston, K., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2016). The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage: Clinical, 11, 53-60.

  • Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2015). Finding the self by losing the self: Neural correlates of ego‐dissolution under psilocybin. Human brain mapping, 36(8), 3137-3153.

  • Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. (2019). Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. Journal of Psychoactive Drugs, 51(2), 123-134.

  • Mueller, F., Lenz, C., Dolder, P. C., Harder, S., Schmid, Y., Lang, U. E., … & Borgwardt, S. (2017). Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Translational psychiatry, 7(4), e1084-e1084.

  • Naranjo, C. (1996). The interpretation of psychedelic experience in light of the psychology of meditation. Sacred plants, consciousness and healing, 75-90.

  • Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018). Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. Journal of Psychopharmacology, 32(7), 756-769.

  • Preller, K. H., Pokorny, T., Hock, A., Kraehenmann, R., Stämpfli, P., Seifritz, E., … & Vollenweider, F. X. (2016). Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proceedings of the National Academy of Sciences, 113(18), 5119-5124.

  • Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., … & Anticevic, A. (2018). Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife, 7, e35082.

  • Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018). Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology, 142, 263-269.

  • Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019). Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. Journal of Psychopharmacology, 33(9), 1076-1087.

  • Smigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019). Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. NeuroImage, 196, 207-215.

  • Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., … & Carhart-Harris, R. (2016). Increased global functional connectivity correlates with LSD-induced ego dissolution. Current Biology, 26(8), 1043-1050.

  • Timmermann, C., Roseman, L., Schartner, M., Milliere, R., Williams, L. T., Erritzoe, D., … & Carhart-Harris, R. L. (2019). Neural correlates of the DMT experience assessed with multivariate EEG. Scientific reports, 9(1), 1-13.

  • Watkins, N. W. (2018). (A) phantasia and severely deficient autobiographical memory: Scientific and personal perspectives. Cortex, 105, 41-52.

  • Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. Journal of humanistic psychology, 57(5), 520-564.

CHAPTER 5

  • Almeida, R. N. D., Galvão, A. C. D. M., Da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., … & Galvão-Coelho, N. L. (2019). Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. Frontiers in psychology, 10, 1234.

  • Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., … & Knudsen, G. M. (2017). A high-resolution in vivo atlas of the human brain’s serotonin system. Journal of Neuroscience, 37(1), 120-128.

  • Benneyworth, M. A., Xiang, Z., Smith, R. L., Garcia, E. E., Conn, P. J., & Sanders-Bush, E. (2007). A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Molecular pharmacology, 72(2), 477-484.

  • Bouso, J. C., Dos Santos, R. G., Alcázar-Córcoles, M. Á., & Hallak, J. E. (2018). Serotonergic psychedelics and personality: A systematic review of contemporary research. Neuroscience & Biobehavioral Reviews, 87, 118-132.

  • Carhart-Harris, R. L., & Friston, K. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacological reviews, 71(3), 316-344.

  • Dakic, V., Minardi Nascimento, J., Costa Sartore, R., Maciel, R. D. M., de Araujo, D. B., Ribeiro, S., … & Rehen, S. K. (2017). Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. Scientific reports, 7(1), 1-13.

  • Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of contextual behavioral science, 15, 39-45.

  • De Vos, C. M., Mason, N. L., & Kuypers, K. P. (2021). Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Frontiers in Psychiatry, 1575.

  • Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., … & Barrett, F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational psychiatry, 11(1), 1-10.

  • Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., … & de Araujo, D. B. (2020). Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. Journal of Psychopharmacology, 34(10), 1125-1133.

  • Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., … & Liechti, M. E. (2021). Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology, 46(3), 537-544.

  • Hutten, N. R., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., … & Kuypers, K. P. (2020). Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers. ACS pharmacology & translational science, 4(2), 461-466.

  • Jefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021). Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. Journal of Psychopharmacology, 35(4), 483-493.

  • Katchborian-Neto, A., Santos, W. T., Nicácio, K. J., Corrêa, J. O., Murgu, M., Martins, T. M., … & Paula, A. C. (2020). Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: applicability to Parkinson’s disease. Journal of Ethnopharmacology, 255, 112743.

  • Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016). LSD‐induced entropic brain activity predicts subsequent personality change. Human brain mapping, 37(9), 3203-3213.

  • Lima da Cruz, R. V., Moulin, T. C., Petiz, L. L., & Leão, R. N. (2018). A single dose of 5-MeO-DMT stimulates cell proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus. Frontiers in Molecular Neuroscience, 312.

  • Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., … & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. Cell reports, 23(11), 3170-3182.

  • Morales-Garcia, J. A., Calleja-Conde, J., Lopez-Moreno, J. A., Alonso-Gil, S., Sanz-SanCristobal, M., Riba, J., & Perez-Castillo, A. (2020). N, N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Translational psychiatry, 10(1), 1-14.

  • Murphy-Beiner, A., & Soar, K. (2020). Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers. Psychopharmacology, 237(4), 1161-1169.

  • Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., … & Vollenweider, F. X. (2017). The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Current Biology, 27(3), 451-457.

  • Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., … & Anticevic, A. (2018). Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife, 7, e35082.

  • Szabo, A., Kovacs, A., Riba, J., Djurovic, S., Rajnavolgyi, E., & Frecska, E. (2016). The endogenous hallucinogen and trace amine N, N-dimethyltryptamine (DMT) displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary iPSC-derived cortical neurons and microglia-like immune cells. Frontiers in neuroscience, 10, 423.

CHAPTER 6

  • Barone, W., Beck, J., Mitsunaga-Whitten, M., & Perl, P. (2019). Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. Journal of psychoactive drugs, 51(2), 199-208.

  • Bedi, G., Phan, K. L., Angstadt, M., & De Wit, H. (2009). Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology, 207(1), 73-83.

  • Carhart-Harris, R. L., Wall, M. B., Erritzoe, D., Kaelen, M., Ferguson, B., De Meer, I., … & Nutt, D. J. (2014). The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. International Journal of Neuropsychopharmacology, 17(4), 527-540.

  • Dahlgren, M. K., Laifer, L. M., VanElzakker, M. B., Offringa, R., Hughes, K. C., Staples-Bradley, L. K., … & Shin, L. M. (2018). Diminished medial prefrontal cortex activation during the recollection of stressful events is an acquired characteristic of PTSD. Psychological medicine, 48(7), 1128-1138.

  • Edsinger, E., & Dölen, G. (2018). A conserved role for serotonergic neurotransmission in mediating social behavior in octopus. Current Biology, 28(19), 3136-3142.

  • Francati, V., Vermetten, E., & Bremner, J. D. (2007). Functional neuroimaging studies in posttraumatic stress disorder: review of current methods and findings. Depression and anxiety, 24(3), 202-218.

  • Gamma, A., Buck, A., Berthold, T., Hell, D., & Vollenweider, F. X. (2000). 3, 4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H215O]-PET in healthy humans. Neuropsychopharmacology, 23(4), 388-395.

  • Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., … & Liechti, M. E. (2020). Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology, 45(3), 462-471.

  • Hope, R., 2015. In: McMillan, K. (Ed.), Is Ecstasy the Key to Treating Women with PTSD? Marie Claire.

  • Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, C., … & Liechti, M. E. (2014). MDMA enhances emotional empathy and prosocial behavior. Social cognitive and affective neuroscience, 9(11), 1645-1652.

  • Kamilar-Britt, P., & Bedi, G. (2015). The prosocial effects of 3, 4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. Neuroscience & Biobehavioral Reviews, 57, 433-446.

  • Kuypers, K. P., Dolder, P. C., Ramaekers, J. G., & Liechti, M. E. (2017). Multifaceted empathy of healthy volunteers after single doses of MDMA: a pooled sample of placebo-controlled studies. Journal of Psychopharmacology, 31(5), 589-598.

  • Lefevre, A., Richard, N., Jazayeri, M., Beuriat, P. A., Fieux, S., Zimmer, L., … & Sirigu, A. (2017). Oxytocin and serotonin brain mechanisms in the nonhuman primate. Journal of Neuroscience, 37(28), 6741-6750.

  • Nardou, R., Lewis, E. M., Rothhaas, R., Xu, R., Yang, A., Boyden, E., & Dölen, G. (2019). Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature, 569(7754), 116-120.

  • Stein, D. J., & Vythilingum, B. (2009). Love and attachment: the psychobiology of social bonding. CNS spectrums, 14(5), 239-242.

  • Thompson, M. R., Li, K. M., Clemens, K. J., Gurtman, C. G., Hunt, G. E., Cornish, J. L., & McGregor, I. S. (2004). Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA (‘Ecstasy’) in rats. Neuropsychopharmacology, 29(4), 694-704.

  • Tatera, K. (2016). Meet a Former Soldier Who Overcame His Life-Threatening PTSD With MDMA-Therapy. The Science Explorer.

  • Thompson, M. R., Hunt, G. E., & McGregor, I. S. (2009). Neural correlates of MDMA (“Ecstasy”)-induced social interaction in rats. Social neuroscience, 4(1), 60-72.

  • Wigton, R., Radua, J., Allen, P., Averbeck, B., Meyer-Lindenberg, A., McGuire, P., … & Fusar-Poli, P. (2015). Neurophysiological effects of acute oxytocin administration: systematic review and meta-analysis of placebo-controlled imaging studies. Journal of Psychiatry and Neuroscience, 40(1), E1-E22.

  • Young, K. A., Liu, Y., & Wang, Z. (2008). The neurobiology of social attachment: a comparative approach to behavioral, neuroanatomical, and neurochemical studies. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 148(4), 401-410.

CHAPTER 7

  • Breeksema, J. J., & van Elk, M. (2021). Working with weirdness: a response to “Moving Past Mysticism in Psychedelic Science”. ACS pharmacology & translational science, 4(4), 1471-1474.

  • Budisavljevic, M. N., Stewart, L., Sahn, S. A., & Ploth, D. W. (2003). Hyponatremia associated with 3, 4-methylenedioxymethylamphetamine (“Ecstasy”) abuse. The American journal of the medical sciences, 326(2), 89-93.

  • Burgess, C., O’donohoe, A., & Gill, M. (2000). Agony and ecstasy: a review of MDMA effects and toxicity. European psychiatry, 15(5), 287-294.

  • Carhart-Harris, R. (2013). Psychedelic drugs, magical thinking and psychosis. Journal of Neurology, Neurosurgery and Psychiatry, 84(9), e1.

  • Domínguez-Clavé, E., Soler, J., Pascual, J. C., Elices, M., Franquesa, A., Valle, M., … & Riba, J. (2019). Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits. Psychopharmacology, 236(2), 573-580.

  • Nayak, S. M., Gukasyan, N., Barrett, F. S., Erowid, E., & Griffiths, R. R. (2021). Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry, 54(05), 240-245.

Do you want to read more? Take a look at Irene’s social networks: